X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 33.8 27.7 122.4% View Chart
P/BV x 17.2 2.1 812.3% View Chart
Dividend Yield % 0.7 0.2 274.1%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
IPCA LABS
Mar-17
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs877643 136.4%   
Low Rs424503 84.2%   
Sales per share (Unadj.) Rs223.4254.4 87.8%  
Earnings per share (Unadj.) Rs31.116.1 193.3%  
Cash flow per share (Unadj.) Rs40.329.8 135.3%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.2 440.5%  
Book value per share (Unadj.) Rs219.5194.6 112.8%  
Shares outstanding (eoy) m33.07126.20 26.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.3 129.2%   
Avg P/E ratio x20.935.7 58.7%  
P/CF ratio (eoy) x16.119.2 83.9%  
Price / Book Value ratio x3.02.9 100.6%  
Dividend payout %16.16.2 258.6%   
Avg Mkt Cap Rs m21,50472,300 29.7%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,1286,960 16.2%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m7,38932,106 23.0%  
Other income Rs m167226 74.0%   
Total revenues Rs m7,55632,332 23.4%   
Gross profit Rs m1,7934,448 40.3%  
Depreciation Rs m3041,730 17.6%   
Interest Rs m366241 152.1%   
Profit before tax Rs m1,2902,703 47.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309675 45.7%   
Profit after tax Rs m1,0272,028 50.7%  
Gross profit margin %24.313.9 175.2%  
Effective tax rate %23.925.0 95.8%   
Net profit margin %13.96.3 220.1%  
BALANCE SHEET DATA
Current assets Rs m3,68117,340 21.2%   
Current liabilities Rs m3,1239,559 32.7%   
Net working cap to sales %7.624.2 31.2%  
Current ratio x1.21.8 65.0%  
Inventory Days Days89100 89.2%  
Debtors Days Days5957 103.2%  
Net fixed assets Rs m7,68520,779 37.0%   
Share capital Rs m331252 131.0%   
"Free" reserves Rs m6,67024,499 27.2%   
Net worth Rs m7,25924,553 29.6%   
Long term debt Rs m9553,517 27.1%   
Total assets Rs m11,95739,595 30.2%  
Interest coverage x4.512.2 37.0%   
Debt to equity ratio x0.10.1 91.8%  
Sales to assets ratio x0.60.8 76.2%   
Return on assets %11.75.7 203.4%  
Return on equity %14.28.3 171.4%  
Return on capital %20.710.5 197.6%  
Exports to sales %39.448.6 80.9%   
Imports to sales %5.714.2 40.0%   
Exports (fob) Rs m2,90815,617 18.6%   
Imports (cif) Rs m4214,571 9.2%   
Fx inflow Rs m3,44515,617 22.1%   
Fx outflow Rs m7035,828 12.1%   
Net fx Rs m2,7439,790 28.0%   
CASH FLOW
From Operations Rs m1,4402,764 52.1%  
From Investments Rs m-1,089-1,432 76.1%  
From Financial Activity Rs m-353-1,591 22.2%  
Net Cashflow Rs m-1-259 0.6%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS